Please assess the completion status of the following clinical trial:

Trial Title: Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Participants who met the following criteria were eligible for this study:~Inclusion Criteria:~* History of AR documented by the investigator, as follows:~  * At least a 1-year clinical history (6-month history if the participant was \>= 2 to \< 4 years of age) of perennial allergic rhinitis (PAR); or a clinical history of seasonal allergic rhinitis (SAR) over 2 seasons and~ * positive skin test (prick or intradermal) to a seasonal or perennial allergen that was present in the participant's environment at time of screening.~* Written informed consent and ability of parent/legal guardian of the participant to give a written informed consent before any study related procedures. Participants \>=7 years of age (or younger according to the governing institutional review board \[IRB\]) had to provide a signed assent form~Exclusion Criteria:~* Concomitant medical condition that might have interfered with the administration of a nasal spray, including anatomical abnormalities of the nose, face (eg, polyposis, markedly deviated septum)~* Presence of any active, untreated, or clinically significant musculoskeletal, endocrinologic, gastrointestinal, hepatic, respiratory, cardiovascular, or neurological condition that might have interfered with the study~* Any conditions or treatment that might have affected the HPA axis or the plasma cortisol assay, including but not limited to:~  * Documented disorder involving the hypothalamus, pituitary, or adrenal gland~ * Current use of serotonergic, dopaminergic, adrenergic, cholinergic agonists and antagonists, opiates, immunomodulatory, hormonal drugs, and lipid-lowering agents~ * Treatment with systemic corticosteroids (oral, intravenous, intramuscular, or intra-articular) within 3 months prior to Visit 1~ * Treatment with systemic corticosteroids for \> 2 courses received up to 1 year before Visit 1 was exclusionary. Up to 2 courses of systemic corticosteroids, each course not exceeding 14 days, up to 1 year before Visit 1 was allowed~ * Treatment with inhaled, intranasal, or high-potency topical corticosteroids within 6 weeks of Visit 1~ * History of hospitalization due to asthma within 1 year before screening. Participants with mild asthma that was well-controlled without the use of inhaled corticosteroids within 6 weeks prior to Visit 1 were eligible for the study~* Any clinically significant (as determined by the investigator) abnormal laboratory test at Visit 1~* Morning serum cortisol outside the reference range at Visit 1~* Any of the following missing serum cortisol samples from the Visit-2 collection: first sample (before administration of investigational product), 20-hour sample, 24-hour sample, or any 2 consecutive samples~* Any medical condition where use of corticosteroids might have been contraindicated or could have led to disease exacerbation (eg, glaucoma, cataract, ocular herpes simplex, tuberculosis, growth retardation)~* History of hypersensitivity to corticosteroids or to the rescue medication, investigational product, or to any of their excipients~* Unresolved upper respiratory tract infection, sinus infection, or nasal candidiasis (ie, symptomatic or under treatment) within the last 2 weeks prior to Visit 1 and Visit 3~* Females of childbearing potential not protected by effective contraceptive method of birth control or were unwilling to abstain from sexual activity and/or, were unwilling or unable to test for pregnancy. Only female adolescent with onset of menses were to be checked by serum pregnancy test at Visit 1~* Pregnant female adolescent (who tested positive for pregnancy at Visit 1) The above information was not intended to contain all considerations relevant to potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): * placebo during the screening phase and~* placebo during the treatment phase.~All children had the option to take rescue medication, (Claritin®) as needed to relieve symptoms of AR.
- TAA-AQ (Type: EXPERIMENTAL): * placebo during the screening phase and~* TAA-AQ (Nasacort AQ) during the treatment phase.~All children had the option to take rescue medication, (Claritin®) as needed to relieve symptoms of AR.

Based on this trial design, predict the completion outcome and termination type (if applicable).